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Abstract
Perturbations to mammalian SWI/SNF (BAF) complexes contribute to over 20% of human 
cancers, with driving roles first identified in malignant rhabdoid tumor (MRT), an aggressive 
pediatric cancer characterized by biallelic inactivation of the core BAF complex subunit 
SMARCB1 (BAF47). However, the mechanism by which this alteration contributes to 
tumorigenesis remains poorly understood. We find that BAF47 loss destabilizes BAF complexes 
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on chromatin, absent significant changes in intra-complex integrity. Rescue of BAF47 in BAF47-
deficient sarcoma cell lines results in increased genome-wide BAF complex occupancy, 
facilitating widespread enhancer activation and opposition of polycomb-mediated repression at 
bivalent promoters. We demonstrate differential regulation by BAF and PBAF complexes at 
enhancers and promoters, respectively, suggesting distinct functions of each complex which are 
perturbed upon BAF47 loss. Our results demonstrate collaborative mechanisms of mSWI/SNF-
mediated gene activation, identifying functions that are coopted or abated to drive human cancers 
and developmental disorders.
Introduction
Chromatin regulation is critical for the maintenance of timely and appropriate gene 
expression, with epigenetic regulators playing key roles both in normal development and 
oncogenesis1. Chromatin remodeling complexes regulate DNA accessibility via alteration of 
nucleosome positioning and/or occupancy in an ATP-dependent manner2. One of the most 
well-characterized chromatin remodeling complexes is the mammalian SWI/SNF (BAF) 
complex, first identified in yeast3 and subsequently characterized in Drosophila4 and 
mammals5. Specialized BAF complex subunit configurations have been demonstrated to be 
critical in pluripotency6,7, neural differentiation8, as well as the development of several other 
adult tissue types9. Various epigenetic modifiers and chromatin remodeling complexes, 
including BAF complexes, have been shown to localize to active promoters and enhancers in 
ES cells10,11, however, the roles for specific complexes in the establishment and 
maintenance of promoter and enhancer states are not well understood.
Evidence for a driving role of BAF complex alterations in cancer was first documented in 
malignant rhabdoid tumor (MRT), a highly aggressive pediatric cancer12, in which the 
SMARCB1 gene, which encodes the core BAF complex subunit BAF47 (also known as 
INI1, hSNF5), undergoes biallelic inactivation in ∼98% of MRT cases12,13. BAF47 loss has 
since been shown to be the hallmark genetic alteration in additional cancer types including 
atypical teratoid/ rhabdoid tumors (AT/RT; ∼100%)14 and epithelioid sarcomas (EpS; 
>90%)15. Additionally, BAF47 mutations are implicated in the development of 
meningiomas16, schwannomatosis17, and Coffin-Siris syndrome18. MRTs are genomically 
stable sarcomas with extremely low mutational burden19,20, and conditional biallelic 
inactivation of Smarcb1 in a mouse model leads to the most rapid tumorigenesis documented 
for a single gene deletion, with median onset at 11 weeks21. Recent exome sequencing 
studies have demonstrated that genes encoding BAF complex subunits are mutated in >20% 
of human cancers22, including gain-of-function perturbations such as the SS18-SSX 
oncogenic fusion hallmark to ∼100% of synovial sarcomas23. The clear link between 
SMARCB1 deletion and MRT suggests MRT as a uniquely powerful disease setting in 
which to understand BAF complex mutations across human cancer.
Dynamic opposition between BAF complexes and polycomb repressive complexes was first 
demonstrated genetically in Drosophila4,24, and has since been shown to govern critical 
processes in both normal development and disease25. In mammals, this opposition has been 
suggested to occur in a locus-specific manner26,27, and in a global regulatory manner 
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through upregulation of Ezh28. In synovial sarcoma, the oncogenic SS18-SSX fusion has 
been demonstrated to direct BAF complexes to new genomic loci such as SOX2, opposing 
polycomb-mediated repression, and leading to oncogene activation23. More recently, 
mechanistic studies have demonstrated that BAF-polycomb complex opposition occurs on 
chromatin in a rapid, ATP-dependent manner, with loss of BAF47 leading to significant 
diminution in the ability of BAF complexes to oppose polycomb-mediated repression29. 
PRC2 complexes play particularly critical roles in maintaining bivalent gene promoters, 
marked dually by H3K4me3 and H3K27me330,31. The bivalent state of a given locus is 
maintained by a balance between activating trithorax (Trx) proteins (such as MLLs) and 
repressive polycomb group (PcG) proteins (such as PRC2 components)32, with several BAF 
complex subunits also categorized as trithorax-group proteins24. Loss of PRC2 leads to 
activation of tissue-specific bivalent promoters but not monovalent promoters marked by 
H3K27me3 only33. Pre-clinical studies (and now early-stage clinical studies) using EZH2 
inhibitors in BAF47-deficient sarcoma model systems have begun to show promise34, 
suggesting this dynamic opposition as a critical mediator of oncogenesis in BAF47-deficient 
sarcomas.
We sought to understand how loss of BAF47, a core BAF complex subunit, affects the 
stability, targeting and gene expression regulation of BAF complexes in sarcomas driven by 
loss of BAF47. We determined that loss of BAF47 destabilizes the association of BAF 
complexes on chromatin, without greatly impairing complex stability or assembly. Rescue of 
BAF47 in MRT and EpS cell lines drives a major gain of genome-wide BAF complex 
occupancy and enhancer state activation across the genome. In addition, we find that rescue 
of BAF47 targets BAF complexes to bivalent promoters, enabling opposition of polycomb-
mediated repression to resolve bivalent promoters to activation. Finally, we demonstrate that 
the observed enhancer activation and resolution of bivalent promoters are collaborative with 
respect to gene expression, suggesting dual complementary roles for BAF47-mediated tumor 
suppression. These data suggest two defining functions of BAF complexes that can be singly 
or collaboratively perturbed in BAF complex-mutated cancers and developmental disorders.
Results
BAF47 loss decreases chromatin affinity of intact BAF complexes
BAF47 is a core BAF complex subunit that is stable in its association with the BRG1 
ATPase subunit in over 2M urea treatment23. To determine the effect of BAF47 loss on the 
integrity and subunit stability of BAF complexes, we lentivirally infected the G401 MRT 
cell line with either full-length BAF47 or an empty vector control (Fig. 1a). Nuclear protein 
levels of core BAF subunits, both total and BAF-bound, were largely unchanged upon rescue 
of BAF47 (Fig. 1b). BAF47 rescue was accompanied by minimal changes to BAF complex-
bound protein levels of most core subunits in anti-BRG1 immunoprecipitations (IPs) (Fig. 
1b, Supplementary Fig. 1a). To confirm this, we generated BAF47Δ/ΔHEK293T cells using 
CRISPR/Cas9-mediated knockout and again did not observe changes in either total or BAF 
complex-bound protein levels (Fig. 1c). Silver stain analyses of anti-BRG1 and anti-
BAF250A IPs from nuclear protein demonstrated highly similar banding patterns in both 
conditions (Fig. 1d, Supplementary Fig. 1b). To complement this, we used low-stringency 
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anti-BRG1 affinity purification/ proteomic mass-spectrometry (Fig. 1e, Supplementary Table 
1). Peptide abundance corresponding to most BAF complex subunits were roughly 
equivalent in both conditions, with the exception of the BAF45A/D and BAF60C subunits, 
which exhibited increases upon BAF47 rescue, possibly indicating their direct tethering to 
BAF47. Prior studies examining changes in complex subunit composition upon loss of the 
BAF47 subunit have been conflicting, with some showing dissociation of BAF 
complexes35,36 and others suggesting no changes to BAF complex assembly29,37-39, likely 
due to differences in chromatin-bound protein purification methods and effects of super-
stoichiometric protein abundance resulting from strong overexpression. Additionally, harsh 
denaturing detergents, such as sodium dodecyl sulfate (SDS) and sodium deoxycholate, used 
in some of these experiments can disrupt protein-protein complex interactions and/or reduce 
the antibody pulldown efficacy in solution (Supplementary Fig. 1e-f).
In order to examine changes to the biochemical stability and size of BAF complexes, we 
performed 10-30% glycerol gradient-based density sedimentation analyses in G401 nuclear 
extracts in both empty vector and BAF47 conditions (Fig. 1f-g, Supplementary Fig. 1c). 
BAF47 fully incorporates into BAF complexes upon re-expression (fractions 13-15), and 
subunits corresponding to both BAF and PBAF complexes shift up by approximately 1-2 
fractions, in accordance with the expected gain in complex mass resulting from BAF47 and 
associated subunits (from Fig. 1e). Select subunits, including BRG1 and BAF60A, exhibit a 
greater spread across gradient fractions in the absence of BAF47, however BRG1-bound 
subunit stability was largely retained as demonstrated by urea desaturation experiments 
(Supplementary Fig. 1d). Collectively, these results demonstrate that loss of BAF47 does not 
affect global protein abundance or complex incorporation of most BAF complex subunits, 
nor does it render the complex wholly unstable in solution as may have been predicted given 
its high degree of evolutionary conservation and its highly penetrant loss-of-function 
phenotype.
As BAF chromatin remodeling complexes contain several DNA- and histone-binding 
domains, we sought to determine if BAF47 loss alters the stability of BAF complexes on 
chromatin. We used NaCl-based differential salt extraction to determine the relative affinity 
of BAF complex proteins on chromatin in G401 cells containing either empty vector control 
or BAF47 (Fig. 1h, left, Supplementary Fig. 2a). We found that BAF47-deficient complexes 
in G401 cells dissociate from chromatin between 150-300 mM NaCl, while upon BAF47 
rescue, subunits dissociate from chromatin between 500-1000 mM NaCl treatment (Fig. 1h, 
right, Fig. 1i, Supplementary Fig. 2b-c). As controls, we assessed PRC2 subunits EZH2 and 
SUZ12, and observed no changes in chromatin dissociation between conditions 
(Supplementary Fig. 2d). Results were similar in comparing BAF complex chromatin 
affinity in wild-type and BAF47-knockout HEK293T cells (Supplementary Fig. 2e-g). These 
results indicate that the primary biophysical consequence of BAF47 loss is decreased affinity 
of BAF complexes for chromatin, suggesting alterations in their chromatin occupancy and 
regulatory capacity.
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BAF47 rescue drives a widespread gain in BAF complex occupancy
To examine the effect of BAF47 rescue on BAF complex targeting and gene regulation, we 
lentivirally infected two MRT cell lines, TTC1240 and G401, with empty vector or BAF47, 
as above (Fig. 2a), and performed chromatin immunoprecipitation of BAF complexes 
followed by sequencing (ChIP-seq) using antibodies to two core BAF complex subunits, 
BRG1 and BAF155. We observed a striking gain of genome-wide BAF complex occupancy 
upon rescue of BAF47 in TTC1240 cells (Fig. 2b-d, Supplementary Fig. 3a-e). We found 
that gained (BAF47-only) BAF complex sites (defined as shared BRG1-BAF155 sites) in 
TTC1240 cells are disproportionately localized to promoter-distal regions, as compared to 
conserved (empty-BAF47) BAF complex sites (Fig 2e, Supplementary Fig. 3f-g). Gained 
BAF complex sites were selectively enriched for unique motifs such as the AP-1 motif (Fig. 
2f, Supplementary Fig. 3h). In addition, we examined the 46-way vertebrate PhyloP 
evolutionary conservation scores at all conserved and gained BAF complex sites upon 
BAF47 reintroduction in TTC1240 cells, and found that gained sites were much less 
evolutionarily conserved than conserved sites (Fig. 2g). This pattern was observed at both 
proximal and distal BAF complex sites (Supplementary Fig. 3i-j) and suggests that sites 
which lose BAF complex regulation upon BAF47 deletion in MRT are more recently 
evolved, implicating an evolutionarily recent cell of origin from which MRTs arise. These 
results demonstrate a widespread gain of BAF complex chromatin occupancy driven by 
BAF47 rescue, and further, show that BAF47-rescued BAF complex sites are distinct in 
localization and predicted functional properties from conserved BAF complex sites.
We next sought to determine the sensitivity of BAF47-deficient sarcoma cell lines spanning 
MRT (4), EpS (4), and AT/RT (2) types, to BAF47 rescue (Supplementary Table 2). We 
found that all MRT and AT/RT cell lines assessed exhibited marked proliferative arrest upon 
BAF47 rescue, however this occurred in only one of the four EpS cell lines, with three EpS 
cell lines showing no significant proliferative arrest upon BAF47 rescue (Fig. 2h, 
Supplementary Fig. 4).
To validate our genome-wide findings from TTC1240 cells, and to decouple changes from 
BAF47 reintroduction and subsequent proliferative suppression, we performed ChIP-seq for 
BRG1 and BAF155 in G401, HS-ES-2M, and VA-ES-BJ cells, and observed a similar gain 
in BAF complex occupancy upon BAF47 rescue to promoter-distal sites, irrespective of the 
cell line used (Fig. 2i-k, Supplementary Fig. 5). These data demonstrate that reintroduction 
of the BAF47 subunit drives a consistent, widespread gain of genome-wide BAF complex 
occupancy across distinct BAF47-deficient sarcoma subtypes, independent of sensitivity to 
BAF47-mediatedgrowth suppression.
BAF47 is required for BAF complex-mediated enhancer activation
To determine the effect of gained BAF complex occupancy on the histone landscape, we 
performed ChIP-seq studies for H3K4me3, H3K4me1, and H3K27ac marks. Notably, we 
found significant gains in H3K27ac and H3K4me1, but very minor changes in H3K4me3 
levels (Fig. 3a), suggesting that gained BAF complex occupancy predominantly determines 
both enhancer state and enhancer activation40. We find that this activation is specific to distal 
enhancer sites (Fig. 3b-d), and observed similar gains in enhancer activation across all cell 
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lines studied (Supplementary Fig. 6). In addition, we noted the presence of enhancer sites 
which retain BAF complex occupancy and activation irrespective of BAF47 status, 
suggesting alternate activators at these sites. We found a strong correlation between the log2 
fold change in occupancy of BRG1 and H3K27ac (PCC=0.82) over all TTC1240 BAF sites 
(in both Empty and BAF47 conditions), with a lower but strong correlation with H3K4me1 
(PCC=0.56), likely due to relative antibody enrichment, while we observed minimal 
correlations with H3K4me3 (PCC=0.15) (Fig. 3e, Supplementary Fig. 7a-c). These results 
indicate that in addition to BAF complex- mediated enhancer state and activation, the levels 
of BAF complex occupancy directly correspond to degree of enhancer activation.
Connecting BAF47-mediated enhancer gain to gene expression, we find that the number of 
gained distal BAF sites associated with a target gene correlated with greater gene activation 
in TTC1240 cells (Fig. 3f) and G401 cells (Supplementary Fig. 7d). Given that clusters of 
enhancers mediate the greatest degrees of gene activation, we sought to determine if BAF47 
activates only enhancers or super-enhancers. We found that significant enhancer activation 
upon rescue of BAF47 occurs at both typical enhancers (12875) and super-enhancers (283), 
and that both typical and super-enhancers are retained in the absence of BAF47 (Fig. 3g, 
Supplementary Fig. 7e-f), in contrast to previous reports35.
We then performed chromosome conformation capture followed by massively parallel 
sequencing (Hi-C) in VA-ES-BJ cells to determine if BAF47 rescue affects global chromatin 
topology independent of proliferative arrest, as this has been a suggested mechanism of 
oncogenesis in other cancers41,42. While we found that BAF47 had no significant impact on 
global genome architecture (Supplementary Fig. 8a-e), we did identify new promoter-
enhancer interactions at gained enhancers such as CDKN1A (Supplementary Fig. 8f), likely 
due to downstream effects of enhancer activation. These results collectively suggest that 
BAF47 plays a key role in mediating activation of constituent enhancers at both typical and 
super-enhancer clusters, with large clusters of de novo gained BAF complex target sites 
promoting greatest gene activation.
Enhancer activation is mediated by BAF not PBAF complexes
Mammalian SWI/SNF complexes exist in two different assemblies, canonical BAF 
complexes and PBAF complexes, defined by distinct subunits (Fig. 4a), with BAF47 as a 
shared core subunit in both. Given that both BAF and PBAF complexes remain intact in the 
absence of BAF47 (Fig. 4b), we performed ChIP-seq for SS18 (BAF complex-specific)43 
and BAF200/ARID2 (PBAF complex-specific) to determine how rescue of BAF47 
influences each complex. We found that SS18 exhibits substantially more retargeting than 
BAF200, with SS18 retargeted in a similar manner as BRG1 and BAF155, while BAF200 
exhibited only modest retargeting over all TTC1240+BAF47 BRG1-BAF155 shared sites 
(Fig. 4c). We find that SS18-marked BAF complexes exhibit a dramatic gain of occupancy at 
distal sites, whereas gains in BAF200-marked PBAF complexes are nearly entirely restricted 
to proximal sites (Fig. 4d-f, Supplementary Fig. 9a). Using log2 fold changes in BRG1, 
SS18, and BAF200 occupancy upon BAF47 reintroduction, we find that BRG1 and SS18 
exhibit high correlation (PCC = 0.88), while BRG1 and BAF200 exhibit a substantially more 
modest correlation (PCC = 0.49) (Fig. 4g-h, Supplementary Fig. 9b). BRG1 and BAF200 
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exhibit stronger correlations at proximal (0.56) than distal (0.43) sites, whereas BRG1 and 
SS18 correlations are similar (proximal PCC=0.82, distal PCC=0.86), suggesting a greater 
role for retargeting of PBAF complexes to proximal sites (Supplementary Fig. 9c-d). These 
results demonstrate a disproportionate targeting of BAF complexes to enhancers and PBAF 
complexes to promoters, with BAF47 driving widespread enhancer activation by BAF and 
not PBAF complexes, as PBAF complexes are not significantly targeted to these sites (Fig. 
4i).
BAF47 rescues BAF complex-mediated resolution of bivalency
Loss of the opposition between BAF complexes and polycomb repressive complex 2 (PRC2) 
has been extensively implicated in MRT, suggesting both mechanisms of global regulatory 
opposition28 and locus-specific opposition (e.g. at the p16INK4A locus)26. However, to date, 
BAF-polycomb complex opposition has not been studied at a genome-wide level. We 
performed ChIP-seq for SUZ12 (a core PRC2 subunit) and H3K27me3, and find that over 
all promoters, occupancy of BAF and PBAF complexes correlates with H3K4me3 
occupancy as well as gene expression, whereas H3K27me3 and SUZ12 exhibit highest 
occupancy at non-expressed genes (Fig. 5a, Supplementary Fig. 10a-h). This suggests that 
BAF and PBAF complexes play a maintenance role at active promoters even in the absence 
of BAF47. We found a set of bivalent promoters in TTC1240 cells, marked by both 
H3K4me3 and H3K27me3, with 3022 (12.57%) genes categorized as bivalent (Fig. 5a, 
Supplementary Fig. 10i-j). GO term analysis of genes with bivalent promoters strongly 
enriches for genes involved in kidney and neural development, likely reflecting initiation of 
cell lineage-specific regulation (Fig. 5b). We also performed ChIP-seq analyses for SUZ12 
and H3K27me3 in G401 cells, and similar to TTC1240 cells, found that 2470 (10.27%) 
genes are bivalent; interestingly, the large majority (1902) of these bivalent genes were 
shared between G401 and TTC1240 cell lines (Fig. 5c, Supplementary Fig. 10k-l), 
suggesting a concordant, lineage-specific set of bivalent genes in MRT cell lines.
Given that recent studies have demonstrated efficacy of EZH2 inhibitors in MRT cell lines34, 
and that EZH2 inhibitors likely work through activating bivalent genes33, we sought to 
determine whether BAF47 rescue resulted in altered bivalent promoter regulation. We find a 
significant increase in target gene occupancy upon rescue of BAF47 by both BAF and PBAF 
complexes (Fig. 5d, Supplementary Fig. 11a). Interestingly we find that while only 8.03% of 
conserved BRG1 target genes are bivalent, 30.13% of gained BRG1 target genes are bivalent 
in TTC1240 cells (Fig. 5e). This results in an increase in BAF complex occupancy at 
bivalent promoters from 29.2% to 68.6% upon rescue of BAF47, the greatest percent 
increase of any promoter category (Supplementary Fig. 11b). We next aimed to assess 
whether the number of bivalent genes is affected by rescue of BAF47. We find that 506 
(16.7%) bivalent genes in the TTC1240-Empty setting are no longer bivalent in the BAF47 
condition (Fig. 5f), suggesting a role for BAF complex-mediated activation at these specific 
sites upon rescue with BAF47.
Examining all BRG1-BAF155 sites in TTC1240+BAF47, we find that rescue of BAF47 
leads to a gain in BAF complex occupancy and a decrease in H3K27me3 occupancy, and 
that this is predominantly at promoter proximal sites (Supplementary Fig. 11c-e). Over all 
Nakayama et al. Page 7
Nat Genet. Author manuscript; available in PMC 2018 March 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
bivalent promoters in TTC1240, we observed a significant decrease in H3K27me3 absent 
changes in H3K4me3 (Fig. 5g, Supplementary Fig. 11f), suggesting the regulation of 
bivalency is solely due to regulation of polycomb-mediated repression, in contrast to 
previous findings26. Over bivalent promoters we observed a gain in both BAF and PBAF 
complex occupancy (Fig. 5h, Supplementary Fig. 11f). Interestingly, log2 fold change values 
over proximal TTC1240 BRG1-BAF155 sites show opposition of BRG1 and H3K27me3 
(PCC=-0.26) and SS18 and H3K27me3 (PCC=-0.24), but opposition is greater between 
BAF200 and H3K27me3 (PCC=-0.40) (Fig. 5i, Supplementary Fig. 11g-i). While we see 
similar results in G401 cells (Supplementary Fig. 12), opposition of polycomb-mediated 
repression is more modest in EpS cell lines, which contain fewer bivalent promoters 
(Supplementary Fig. 13), suggesting that the contribution of bivalency to oncogenesis may 
vary by tissue of origin. Our results demonstrate that BAF complexes, both BAF and PBAF 
complex assemblies, play a critical role in resolving bivalent promoters to activation in 
development, a process significantly impaired by BAF47 loss which leads to reformation of 
bivalency and repression of key developmental and lineage-specific differentiation genes.
Collaborative activation of bivalent promoters and enhancers
Having identified two mechanisms by which BAF47 affects gene activation, by both BAF 
and PBAF complexes, we wanted to determine the relative contribution of each mechanism 
in gene regulation and subsequent tumor suppression. We performed RNA-seq on G401 and 
TTC1240 cell lines with either empty vector or BAF47 (Supplementary Fig. 14a-b). We find 
that bivalent genes are overrepresented in the 2635 significantly-regulated genes in 
TTC1240 cells, with 20.80% marked as bivalent (Fig. 6a). We find that 13.99% of all 
bivalent genes are upregulated by BAF47, the largest proportion of any gene category, and 
that bivalent genes exhibit clear net upregulation as compared to H3K4me3-only genes (Fig. 
6b), with these effects similarly observed in G401 (Supplementary Fig. 14c-d).
We identified a set of 642 genes that are significantly and concordantly regulated in both 
G401 and TTC1240 cells (Fig. 6c-d). GSEA and GO term analyses show that upregulated 
genes play critical roles in kidney development and epithelial-mesenchymal transition 
(EMT), likely suggesting key pathways implicated in BAF47-mediated tumor suppression 
(Fig. 6e-f, Supplementary Fig. 14e-h), which corresponds with mechanisms of MET in 
sarcomagenesis44 along with roles for BAF47 in EMT of pancreatic cancer45. We do not 
observed ownregulation of EZH2 and upregulation of CDKN2A genesin both cell lines, as 
previously suggested (Supplementary Fig. 14i-j). Increases in BAF complex occupancy and 
decreases in PRC2-mediated repression were specific to the promoters of upregulated genes 
upon BAF47 rescue (Supplementary Fig. 15a-f). These results suggest that while MRTs are 
heterogeneous and multi-origin tumors, critical cellular processes such as EMT may be 
regulated by BAF47-containing BAF complexes and altered in BAF47 loss-driven 
sarcomagenesis.
We sought to determine how regulation of enhancers and bivalent promoters cooperate to 
control gene regulation. We categorized genes by the number of conserved (empty-BAF47) 
and gained (BAF47-only) distal BAF complex sites, and found a clear overrepresentation of 
bivalent genes among those with greater numbers of gained distal BAF complex sites(Fig. 
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6g, Supplementary Fig. 14k), and these genes correspond to the upregulation shown 
previously (Fig. 3f). This collaborative activation is exemplified at the CTGF and FN1 loci, 
at which these activated genes gain (1) promoter occupancy that resolves bivalency to 
activation, and (2) numerous distal BAF complex-activated enhancers (Fig. 6h-i). We 
demonstrate here that these enhancer and promoter regulatory functions are hallmark to 
BAF47-mediated gene regulation and tumor suppression, with a critical collaborative role 
for these two distinct BAF complex functions lost in BAF47-deficient cancers.
Discussion
Mutations in the genes encoding BAF complexes are recurrent in over 20% of human 
cancers, as well as several developmental disorders. Here we show that loss of a core BAF 
complex subunit, BAF47, dramatically impairs the chromatin affinity and regulation of BAF 
complexes without significantly impairing in-solution assembly or subunit stability (Fig. 7a). 
We show that BAF complexes play a critical role in mediating enhancer state and activation, 
as well as in resolving bivalent promoters to activation through opposition of polycomb-
mediated repression, and that these activities collaborate in BAF47-driven gene activation 
and tumor suppression in MRT cell lines (Fig. 7b). Our data suggest a broad-reaching role 
for BAF complexes in directing cell state through regulation of developmental enhancers 
and bivalent promoters that may contribute to numerous cancers and developmental 
disorders characterized by BAF complex perturbations.
Understanding the role of BAF47 in the stability and assembly of BAF complexes has been 
a challenge in the field, with contradicting studies suggesting either little change in complex 
composition29,37-39 or dramatic loss of stability35,36 upon BAF47 loss. We do not find global 
changes in BAF complex composition or assembly, in agreement with recent yeast SWI/SNF 
studies46. The structural integrity of BAF47-deficient residual BAF complexes shown here 
indeed supports previous observations of BRG1 dependency in MRT cell lines39, and 
suggests therapeutic avenues for targeting these intact residual BAF complexes in MRT. Our 
results suggest this dependency is due to a retained and required regulation by BAF and 
PBAF complexes, largely at active promoters, in the absence of BAF47.
The opposition between BAF complexes and polycomb complexes is a critical mechanism 
that has been extensively implicated through genetic and mechanistic studies in 
cancer23,26,28,29. Our results reaffirm the BAF complex as a trithorax-group protein through 
opposition of polycomb-mediated repression. This study substantiates how BAF complexes, 
within the existing dynamics of trithorax (Trx) or polycomb (PcG) proteins, drive resolution 
of bivalent promoters toward activation or repression, respectively32. These results begin to 
explain the observed therapeutic efficacy of EZH2 inhibitors in BAF47-deficient sarcomas, 
and suggest a mechanistic synergy between EZH2 inhibition and BAF47 rescue, particularly 
in the control of bivalent promoters. We demonstrate a broad-spanning role for BAF 
complexes at both bivalent promoters and enhancers, which, when perturbed, may explain 
the outsized role for this complex in human disease.
We establish that BAF47 drives a widespread gain of BAF complex occupancy that mediates 
enhancer state as well as enhancer activation. Our results suggest the BAF complex plays a 
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pioneering role in governing enhancer state and activation, such that BAF47 restores the 
functional ability of the BAF complex to bind to and activate these sites. As such, 
recruitment by transcription factors or regulators fails to create BAF complex targeting and 
activation in the absence of BAF47, as previously shown with Arid1a loss promoting 
regeneration47. Enhancers have co-occupancy of numerous chromatin remodelers/
regulators10,48, and our results suggest a dynamic regulation of enhancers by both activating 
(BAF complex) and repressive (NuRD complex)49 remodelers that may be occurring similar 
to HATs and HDACs50. Interruption of this regulatory dynamic via BAF47 loss could then 
decommission a large number of enhancers in the MRT genome, further supporting a critical 
pioneering role for BAF complexes at enhancers.
In summary, our studies demonstrate that reintroduction of BAF47 in BAF47-deficient cells 
triggers a dual gain of BAF complex-mediated activation at enhancers and bivalent 
promoters. We demonstrate that the observed enhancer activation and resolution of bivalency 
to activation are collaborative, leading to activation of key genes involved in cell fate 
determination and tumor suppression. Further studies will be required to determine the 
ordering and relative contributions of these functions in the tumor suppression pathway. Our 
data suggest multiple defining roles for the BAF complex in chromatin activation at 
enhancers and bivalent promoters, each of which could be independently or collaboratively 
perturbed in other BAF complex-driven cancers. Taken together, these data have widespread 
implications for the outsized contribution of BAF complex aberrations in human malignancy 
and developmental disorders.
Methods
Cell lines and tissue culture
Eight MRT cell lines and nine EpS cell lines were used in this study (Supplementary Table 
2). Of these, four cell lines were purchased from ATCC (G401, G402, A204 and VA-ES-BJ), 
and three were from RIKEN (HS-ES-1, HS-ES-2R and HS-ES-2M). TTC1240, TM87-16 
and STM91-01 were a generous gift from Prof. Timothy J. Triche (Children's Hospital Los 
Angeles, Los Angeles, CA), BT12 and BT16 were from Dr. Peter Houghton (The University 
of Texas Health Science Center at San Antonio, TX), NEPS was from Dr. Hiroyuki 
Kawashima (Niigata University Graduate School of Medical and Dental Sciences, Niigata), 
FU-EPS-1 and SFT-8606 were from Prof. Hiroshi Iwasaki (Fukuoka University, Fukuoka), 
YCUS-5 was from Dr. Hiroaki Gotoh (Kanagawa Children's Medical Center, Kanagawa), 
and ESX was from Dr. Tomohide Tsukahara (Sapporo Medical University, Sapporo). Cell 
lines were cultured either in DMEM/F12, RPMI1640, or DMEM medium (Gibco, Grand 
Island, NY, USA), supplemented with 10% fetal bovine serum, 1% Glutamax (Gibco) and 
1% Penicillin-Streptomycin (Gibco).
Vector/cloning information
BAF47 (SMARCB1) constitutive expression in MRT and EpS cell lines was achieved using 
lentiviral infection of an EF1alpha-driven expression vector (modified from Clonetech, dual 
Promoter EF-1a-MCS-PGK-Blast), selected with blasticidin (1ug/ul).
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Lentiviral Generation
Lentivirus was produced by PEI (Polysciences Inc.) transfection of HEK293T LentiX cells 
(Clontech) with gene delivery vector co-transfected with packaging vectors pspax2 and 
pMD2.G as previously described23. Supernatants were harvested 72h post-transfection and 
centrifuged at 20,000 rpm for 2h at 4°C. Virus containing pellets were resuspended in PBS 
and placed on cells dropwise. Selection of lentivirally-infected cells was achieved with 
either blasticydin or puromycin, both used at 2μg/ml.
Nuclear extract
Nuclear extract (NE) preparation and immunoprecipitation (IP) studies were performed as 
described previously in Ho et al. (2009). Briefly, the trypsinized cells were incubated in 
Buffer A (25 mM HEPES pH 7.6, 5 mM MgCl2, 25 mM KCl, 0.05 mM EDTA, 10% 
glycerol and 0.1% NP40 with protease inhibitor (Roche), 1 mM DTT and 1 mM 
phenylmethylsulfonyl fluoride (PMSF)) for 10 minutes and the pellets were resuspended in 
600 μl of Buffer C (10 mM HEPES pH 7.6, 3 mM MgCl2, 100 mM KCl, 0.5 mM EDTA and 
10% glycerol with protease inhibitor, 1 mM DTT and 1 mM PMSF) with 67 μl of 3 M 
(NH4)2SO4 for 20 minutes. The lysates were spun down using ultracentrifuge at 10,000 rpm 
at 4°C for 10 minutes. Nuclear extracts were precipitated with 200 μg of (NH4)2SO4 on ice 
for 20 minutes and finally purified as pellets by ultracentrifugation at 10,000 rpm at 4°C for 
10 minutes. The pellets were resuspended in IP Buffer (150 mM NaCl, 50 mM Tris-HCl pH 
7.5, 1 mM EDTA and 1% Triton-X100 with protease inhibitor, 1 mM DTT and 1 mM 
PMSF) for the subsequent experiments. For the RIPA and IP Buffer comparison experiments 
performed, nuclear pellets were resuspended in either RIPA buffer (150 mM NaCl, 50 mM 
Tris-HCl pH 7.5, 1% Nonidet P-40, 0.5% Sodium Deoxycholate, and0.1% SDS, complete 
with protease inhibitor, 1 mM DTT, and 1 mM PMSF) or IP Buffer (same as above, except 
300 mM NaCl). To analyze the localization of the protein, NE-PER™ Nuclear and 
Cytoplasmic Extraction Reagents (#78833, Thermo Scientific) were used according to the 
manufacture's protocol. The details of the antibodies used for immunoblotting are presented 
in Supplementary Table 3.
Immunoprecipitation
For immunoprecipitation 150-300 μg of nuclear extract was incubated with 1.25 μg of 
antibody in IP Buffer overnight. Then each sample is incubated with Dynabeads (Thermo 
Scientific) for two hours. Beads were washed three times with IP buffer and twice with 
BC100 (20 mM HEPES, 100 mM KCl, 0.2 mM EDTA, 10% Glycerol), and eluted with 20 
μl of sample buffer (NuPage LDS buffer (1×) (Thermo Scientific) and 100 mM DTT).
SMARCB1 Knockout by CRISPR/Cas9 Genome Editing
The SMARCB1 locus was targeted by the Ini1 CRISPR/Cas9 KO Plasmid and Ini1 HDR 
Plasmid (Santa Cruz Biotechnology sc-423027; sc-423027-HDR) in HEK293T Lenti-X cells 
(Clonetech) following the manufacturer's protocol. Specifically, five million HEK293T cells 
were co-electroporated with two plasmids (2 μg DNA/plasmid) using the Amaxa Biosystems 
Nucleofector I and Amaxa Cell Line Nucleofector Kit V. After nucleofection, cells were 
expanded for 48 hours and GFP+/RFP+ cells expressing both the KO/HDR plasmids were 
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single-cell sorted through FACS (fluorescence-activated cell sorting). Single-cell clones 
were expanded further and screened through immunoblot for identification of successful 
knockouts.
2D/LC/MS IP Proteomics
4 samples for each cell type were prepared (2 IgG controls and 2 replicates of anti-
BRG1IPs) for mass spec analysis (label free quantitation). Eluted proteins from each 
condition were processed simultaneously to reduce sample variability. Proteins were 
reduced, alkylated, and digested with trypsin, and desalted using offline C18 reversed-phase 
chromatography. Purified peptides were separated by online C18 reversed-phase 
chromatography then analyzed with a top10 CID data-dependent manner using an LTQ-
Velos mass spectrometer51.
2D/LC/MS IP Proteomics Data Processing and Analysis
Data analysis was performed with MaxQuant software52, supported by a database search 
engine for peptide identification (human IPI). Label-free quantitation algorithms were added 
to MaxQuant by extracting isotope patterns for each peptide in each run.
Density Sedimentation Analyses
Nuclear extract (500 μg) was resuspended in 200 ml of 0% glycerol HEMG buffer and 
carefully overlaid onto a 10 ml 10%–30% glycerol (in HEMG buffer) gradient prepared in a 
14 × 89 mm polyallomer centrifuge tube (331327, Beckman Coulter, Brea, CA, USA). 
Tubes were centrifuged in an SW40 rotor at 4°C for 16 hr at 40,000 rpm. Fractions (0.5 ml) 
were collected and used in analyses.
Urea Denaturation Studies
Nuclear extracts (150 μg) were subjected to partial urea denaturation, ranging from 0.25 to 
5.0 M urea (in IP buffer), for 15 min at room temperature (RT) prior to anti-BRG1 IP. The 
co-precipitated proteins were analyzed by immunoblot.
Differential Salt Extraction
Cell types were grown under standard conditions and following collection of 5×10ˆ7 cells, 
suspended in elution buffer (50 mM Tris-HCl at pH 7.5, 1 mM EDTA, 0.1% NP40) 
supplemented with protease inhibitor mixture (Roche) and 1 mM PMSF, incubated on ice 
for 5 minutes, and centrifuged. Supernatant was collected and pellet was suspended in 
elution buffer with 150 mM NaCl. This process was repeated sequentially with increasing 
concentration of NaCl to collect 0, 150, 300, 500, and 1000 mM NaCl soluble fractions. 
Each fraction, including total fraction (5×10ˆ6 cells in elution buffer) and pellet fraction 
(material remaining following 1000 mM NaCl extraction), was prepared in SDS (final 
concentration of 1%), quantified by Pierce BCA Protein Assay Kit (Thermo Fisher 
Scientific), and analyzed (1.5 μg of protein) by immunoblot. Quantitative densitometry 
analyses were performed with the Li-Cor Odyssey Imaging System (Li-COR Biosciences, 
Lincoln, NE, USA).
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ChIP-seq Data Collection
Cells were harvested following 48-hour exposure to the lenti-virus and 5-day selection with 
10 μg/ml of Blasticidin for chromatin immunoprecipitation (ChIP) experiments. ChIP 
experiments were performed per standard protocols (Millipore, Billerica, MA) with minor 
modifications. Briefly, cells were cross-linked for 10 min with 1% formaldehyde at 37 °C. 
Five million fixed cells were used per chromatin immunoprecipitation experiment. This 
reaction was subsequently quenched with 125 mM glycine for 5 min. Antibodies used for 
ChIP studies are listed in Supplementary Table 3.
RNA Data Collection
Cells were harvested following 48-hour exposure to the lenti-virus and either 1-day (day 3 
post-infection) or 5-day (day 7 post-infection) selection with 10 μg/ml of Blasticidin for 
RNA-seq experiments. RNA-seq samples were prepared in biological duplicate (independent 
lentiviral production, infection, selection, and cell culture). All RNA was produced using the 
RNeasy Mini Kit (Qiagen).
Proliferation experiments
20,000 cells were plated following 48-hour exposure to the lenti-virus and 48-hour selection 
with 10 μg/ml of Blasticidin, with Day 0 denoting the day cells were plated after infection 
and selection. The numbers of viable cells in three wells were measured using Vi-CELL Cell 
Viability Analyzer (Beckman Coulter, Brea, CA) on Day 1, 3, 5 and 7.
Library Prep and Sequencing for ChIP-seq and RNA-seq
All library prep and sequencing (75bp single end on Illuminia Nextseq 500) was performed 
in the Molecular Biology Core Facilities at the Dana-Farber Cancer Institute.
Sequence Data Processing
ChIP-seq reads were mapped to the human reference genome (hg19) using Bowtie253 
version 2.1.0 with parameters –k 1. RNA-seq reads were mapped to the human reference 
genome (hg19) using STAR54 version 2.3.1 with default parameters. All sequence data is 
deposited in the Sequence Read Archive under GSE90634. Summary statistics for 
sequencing experiments are presented in Supplementary Table 4.
ChIP-seq Data Analysis
Peaks were called against input reads using MACS255 version 2.1.0 at q=1e-3. Narrow peak 
calls were used for BRG1, BAF155, SS18, BAF200, and H3K4me3, and broad peak calls 
were used for H3K27ac, H3K4me1, H3K27me3, and SUZ12. Peaks were filtered to remove 
peaks that overlap with ENCODE blacklisted regions, as well as peaks mapped to 
unmappable chromosomes (only chr1-22,X,Y included). Duplicate reads were removed 
using samtools rmdup for all downstream analyses. ChIP-seq track densities were generated 
per million mapped reads with MACS2 2.1.0 using parameters –B –SPMR.
BAF complex sites were determined in each condition using the bedtools overlap of the 
BRG1 and BAF155 sites, and this peak set was used in downstream analyses for 
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determination of BAF complex targeting. Conserved sites were determined as sites with 
peaks overlapping in both empty and BAF47 condition, gained sites were determined using 
sites only in the BAF47 condition. Venn diagrams were generated using the R statistical 
package, using the minimum number of overlapping regions for resolving multiple peak 
overlaps.
Metagene read densities were generated using HTSeq56, with fragment length extended to 
200bp to account for the average 200bp fragment size selected in sonication, using the 
center of peak calls from MACS2. Total read counts for each region were normalized the 
number of mapped reads to give reads per million mapped reads. Metagene plots were 
generated using average read densities across all sites indicated for each condition. 
Heatmaps were generated using the same HTSeq read densities as metagene plots, sites were 
then ranked by mean ChIP-seq signal for the epitope and condition indicated in each figure. 
Heatmaps were visualized using Python matplotlib with a midpoint of 0.5 reads per million 
for the heatmap color scale to set the threshold for visualization.
To generate plots of log2 fold change for ChIP-seq reads, the peak sets for the BAF complex 
(BRG1-BAF155 overlapping sites) in the empty and BAF47 conditions were merged using 
bedtools merge, generating a total of 70777 BRG1-BAF155 sites in TTC1240. ChIP-seq 
read counts for each BAF complex site were generated using Rsubread featureCounts, and 
read counts in each peak region were normalized per million mapped reads. Input RPM 
values for each region in each condition were subtracted from each ChIP epitope in that 
condition, values with higher input enrichment than ChIP enrichment were set to 0. Log2 
fold change values were determined for each ChIP epitope using the normalized RPM values 
above, with a pseudocount of 0.1. Pairwise correlation was determined using a Pearson 
correlation coefficient between normalized fold change values for each pair of ChIP 
experiments.
For motif enrichment analysis, 500bp core sequences centered on peak centers were 
submitted to MEME-ChIP analysis57. Conservation scores were calculated using bedtools 
map –o mean to generate the average PhyloP score for each 500bp core sequence as in motif 
analysis, using the PhyloP 46-way vertebrate conservation score from UCSC58,59. 
Determination of super-enhancers was performed using ROSE60,61 with a union peak set of 
H3K27ac in empty and BAF47 conditions in TTC1240, run with H3K27ac ChIP-seq files in 
empty and BAF47 conditions to determine typical and super-enhancer designations in each 
condition.
Distance to TSS for ChIP-seq peaks was determined using BEDTools closest function with 
hg19 refFlat TSS annotation, with small RNA genes (MIR and SNO) removed. Target genes 
were determined using TSS sites within 2kb of a peak. For visualization of promoters, the 
same promoter set used for target gene analysis was used, except identical promoters with 
multiple annotations were only included once. Number of genes counts each unique gene 
annotation once, whereas number of promoters counts all varied TSS sites that are annotated 
as such, so the number of bivalent genes and bivalent promoters are distinct numbers 
reflecting the same set of sites. Target genes of distal BAF sites were determined using the 
distance to TSS calculations above, filtered for peaks >2k and ≤50kb from their assigned 
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target gene, as most enhancer-promoter interactions have been shown to occur within a 
distance of 50kb62. Genes were then binned by the number of distal BAF sites in each 
condition, and this was used for RNA-seq and promoter state analyses. GO Term analysis 
was performed on the target gene sets using biological processes annotation63, with a 
significance threshold of 1e-3.
RNA-seq Data Analysis
RPKM values for samples were generated using GFold64 version 1.1.0. All error bars 
represent Mean±SEM. Significance was assessed using the R package DESeq265 using raw 
read counts generated with Rsubread feature Counts against the hg19 refFlat annotation. 
Significantly changing genes were assessed with a Bonferri-corrected p-value of less than 
1e-3 and a two-fold gene expression change (|log2FC|>1) to determine set of significantly 
changing genes. GSEA was performed using the GSEA Preranked function of the JAVA 
program (http://www.broadinstitute.org/gsea) as described previously66. Rank files for 
GSEA were generated using RPKMs for duplicate RNA-seq in each cell line, removal of 
short RNAs, filtering for expressed genes (minimum RPKM value for four samples >= 1), 
averaging replicates of each condition, then doing a log2 fold change comparison with a 
pseudocount of 1 in each condition, i.e. log2((RPKMBAF47 + 1)/(RPKMEmpty + 1)). Log2 
fold change values for RNA-seq in figures were identical to those used for GSEA analysis 
except non-expressed genes were included in the analysis. Two-tailed t tests were used to 
determine significance of difference for each.
RNA-seq tracks were generated using bedtools genomecov –split –scale with the mapped 
read count to generate tracks normalized per million mapped reads. All RNA-seq tracks 
visualized are Day 7 post-infection using a representative example in each condition. For 
analysis of significantly changed genes we used Day 3 RNA-seq to capture primary effects 
of tumor suppression before downstream regulation to the extent possible.
Hi-C Experimental Method
Cells were cross-linked with 1% formaldehyde for 10min at room temperature. The Hi-C 
assay was performed as previously described67 with the following modifications. Following 
cross-linking, the cells were lysed and digested with CviQ I + CviA II + Bfa I for 30min. 
Enzymes digested DNA ends were repaired and labeled with biotin-14-dATP with Klenow 
enzyme (large fragment). The proximity-based ligation of chromatin ends was performed 
using T4 DNA Ligase for overnight at 16°C. DNA was reverse cross-linked at 65°C for 6 
hours and purified by phenol-chloroform extraction, which was followed by treatment with 
T4 DNA polymerase to remove biotin from unligated DNA-ends. DNA was sheared to 
300-500bps by sonication. Biotinylated DNA was enriched using streptavidin beads and 
sequencing libraries were generated as described previously.
Hi-C Read Mapping
Sequencing data were obtained from an Illumina HiSeq 2000 machine. The paired-end tags 
(PETs) from Hi-C libraries were mapped to the human reference genome (hg18) using 
bowtie253. Only one uniquely mapped PET were considered at each genome coordinate 
since the mapped PETs with the same coordinate on the genome were considered to be PCR 
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replicates derived from the same original DNA fragments. The uniquely aligned PETs for 
the two biological replicates (Empty and BAF47) were subjected to further.
Hi-C Filtering and Heatmap Analysis
The interaction matrices were binned using a binsize=50 kb, binstep=5kb, binmode=mean. 
First, we generated the matrices from the Hi-C interaction data using binstep of 5kb. Second, 
the self-circularized restriction fragments were filtered by setting the diagonal elements of 
the matrices to be zero. Third, we removed the rows/cols of the matrices if the sum of 
elements in the rows/cols were zero. Fourth, we followed the approach in Hnisz et al.41 to 
calculate the Z-score matrices of the interaction matrices. We detected and flagged the 
elements of the interaction matrices if their corresponding Z-score values were greater than 
21, which were considered as outlier pixel/interactions. We then took the union of all outlier 
pixel/interactions across all the interaction matrices and set them to be zero. Fifth, the 
matrices were balanced according to the KR normalization method68 which was similar to 
the study by Rao et al.67. Sixth, we recovered the interaction matrices with binsize=50kb by 
combining every 10 bins into one bin with binmode=mean. The differential heatmap was the 
subtraction between the matrices in the two conditions.
Analysis for Topological Associating Domains
Each chromosome was separated into 50kb bins and interaction matrix of each chromosome 
was generated for Hi-C data. The interaction matrix was normalized by KR normalization68. 
The normalized interaction matrix was used as input for identifying TAD by Armatus69.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
BAF47 confers BAF complex stability on chromatin without affecting intra-complex subunit 
stability. (a) Schematic for rescue experiments in BAF47-deficient cell lines. (b) Nuclear 
extract inputs and anti-BRG1 IP from G401 nuclear extracts in empty vector and BAF47 
conditions. (c) Nuclear extract input and IPs for IgG, BRG1, and BAF47 in control and 
BAF47Δ/Δ (knockout) HEK293T cells. (d) Silver stain analysis of control IgG and anti-
BRG1 IPs in G401 empty vector and BAF47 conditions. (e) anti-BRG1 IP-mass 
spectrometry proteomics in G401 empty vector and BAF47 conditions for BAF complex 
subunits. (f-g) Density sedimentation analyses using 10-30% glycerol gradients (10m; 
0.5ml/ fx) on nuclear extracts from G401 MRT cells in (f) the empty vector control and (g) 
BAF47 conditions. (h) (left) Schematic for differential salt extraction experiments in G401 
empty vector or BAF47 conditions; (right) Immunoblot analysis of BAF complex subunits in 
differential salt extraction experiments. (i) Relative densitometry from differential salt 
extraction demonstrates gained stability of BAF complexes on chromatin in the BAF47 
condition. Error bars = mean ± SEM for n=2 biological replicates.
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Figure 2. 
Rescue of BAF47 drives a genome-wide gain in BAF complex chromatin occupancy (a) 
Input blot for TTC1240 and G401 cell nuclear extracts in empty vector and BAF47 
conditions. (b) Venn diagram of (left) BRG1 and (right) BAF155 peaks in empty vector and 
BAF47 conditions in TTC1240 cells. (c) Heatmaps of BRG1 and BAF155 occupancy in 
TTC1240 empty vector and BAF47 conditions over all BRG1-BAF155 shared sites in the 
TTC1240+BAF47 condition. (d) Example BRG1, BAF155, and RNA-seq tracks at 
CDKN1A enhancers in TTC1240 cells. (e) Distance to closest transcription start site (TSS) 
for conserved (empty-BAF47) and gained (BAF47-only) BRG1-BAF155 sites in TTC1240 
cells. (f) Centrimo plots for top four centrally enriched motifs at gained BRG1-BAF155 sites 
in TTC1240 cells. (g) Average sequence conservation (PhyloP) of conserved and gained 
BRG1-BAF155 sites. (h) Proliferation analyses of MRT, EpS, and AT/RT cell lines; values 
shown are relative proliferation between BAF47 and empty vector conditions at noted days. 
(i-k) Venn diagrams of BRG1 peaks in empty vector and BAF47 conditions in (i) G401, (j) 
HS-ES-2M, and (k) VA-ES-BJ cell lines.
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Figure 3. 
Gain of BAF complex occupancy drives widespread enhancer activation. (a) Heatmaps of 
BRG1, H3K4me3, H3K4me1, and H3K27ac sites in TTC1240 empty vector and BAF47 
conditions over all BRG1-BAF155 shared sites in the TTC1240+BAF47 condition. 
Heatmaps are ranked by BRG1 occupancy in empty condition. (b-d) Metagene plots of 
BRG1-BAF155 sites in the TTC1240+BAF47 condition split by (left) promoter-proximal 
(≤2kb from TSS), and (right) promoter-distal (>2kb from TSS) for (b) H3K4me3, (c) 
H3K4me1, and (d) H3K27ac occupancy. (e) Correlation plot of log2(fold change) for BRG1 
and H3K27ac over all BRG1-BAF155 sites (70777) in empty or BAF47 conditions. (f) 
Gained promoter-distal BAF complex sites assigned to nearest gene (genes were categorized 
based on number of gained distal sites) versus log2(fold change) in expression. (g) Example 
tracks of BRG1, BAF155, H3K4me3, H3K4me1, H3K27ac, and RNA-seq at the TGM2 
locus in TTC1240 cells.
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Figure 4. 
Enhancer activation upon BAF47 rescue is specific to BAF but not PBAF complexes. (a) 
Schematic of BAF and PBAF complex subunits with subunits targeted for ChIP-seq in 
respective colors. (b) Input and IPs for IgG control, BAF155, BAF250A, and BAF200 from 
HEK293T nuclear extracts in naive and BAF47Δ/Δ conditions. (c) Heatmap of BRG1, 
BAF155, SS18, and BAF200 in TTC1240 empty vector and BAF47 conditions over all 
BRG1-BAF155 shared sites in the TTC1240+BAF47 condition. (d-f) Metagene plots of 
BRG1-BAF155 shared sites in TTC1240+BAF47 split by (left) promoter-proximal (≤2kb 
from TSS), and (right) promoter-distal (>2kb from TSS) for (d) BRG1, (e) SS18, and (f) 
BAF200 occupancy. (g-h) Correlation plot of log2(fold change) for (g) BRG1 and SS18, and 
(h) BRG1 and BAF200, over all TTC1240 BRG1-BAF155 sites in empty or BAF47 
conditions. (i) Example ChIP-seq tracks for BRG1, SS18, BAF200, H3K27ac, and RNA-seq 
at the VIM locus in TTC1240 cells.
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Figure 5. 
Resolution of bivalent promoters to activation by BAF complex-mediated opposition of 
polycomb-mediated repression. (a) Heatmaps of H3K4me3, BRG1, SS18, BAF200, 
H3K27ac, H3K27me3, and SUZ12 across all hg19 promoters in empty vector condition in 
TTC1240 cells, ranked by H3K4me3 occupancy. (b) GO term analysis of bivalent genes in 
TTC1240 cells. (c) Overlap of bivalent genes in G401 and TTC1240 cells. (d) Overlap of 
BRG1 target genes in empty and BAF47 conditions in TTC1240 cells. (e) Distribution of 
(left) conserved and (right) gained BRG1 target genes in TTC1240 cells. (f) Overlap of 
bivalent genes in empty and BAF47 conditions in TTC1240 cells. (g-h) Metagene plots of 
(g) H3K4me3 and H3K27me3, as well as (h) BRG1, SS18, and BAF200, over all 3512 
bivalent promoters in TTC1240 cells. (i) Example tracks at the LAMB1 bivalent promoters 
demonstrate resolution of bivalent promoters to activation upon gain of BAF complex 
occupancy in TTC1240 cells.
Nakayama et al. Page 24
Nat Genet. Author manuscript; available in PMC 2018 March 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. 
Collaborative gene activation by BAF complex-mediated enhancer activation and polycomb 
opposition at bivalent promoters (a) Distribution of significantly-regulated genes in 
TTC1240 cells. (b) Directional regulation of significantly changed genes in TTC1240 cells, 
with y-axis indicating proportion of all genes in each category. (c) (left) Overlap of 
significantly-changed genes in G401 and TTC1240 cell types in empty vector and BAF47 
conditions; (right) genes significantly-regulated in both cell lines show significant 
concordance (p < 2.2e-16, Fisher exact test). (d) Heatmap of 642 significantly changed 
genes in both G401 and TTC1240 cells. Right bar indicates promoter status of each gene in 
each cell line using colors from (a). (e) Heatmap of selected genes that are significantly-
upregulated by BAF47 in both G401 and TTC1240 cells. (f) GO term analysis of 
significantly upregulated genes in both G401 and TTC1240. (g) Genes categorized by 
number of distal gained (BAF47-only) BAF complex sites, broken down by promoter status 
of genes in each category. n = number of genes in each group. (h-i) Example ChIP-seq tracks 
of BRG1, SS18, BAF200, H3K27ac, H3K4me3, H3K27me3, and RNA-seq for (h) CTGF 
and (i) FN1 shows collaborative gene activation via enhancer activation and polycomb 
opposition at bivalent promoters.
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Figure 7. 
BAF47 restores BAF complex affinity and functional regulation of chromatin (a) BAF47 
rescues the biochemical association of BAF complexes with chromatin, absent major 
changes in subunit composition or intra-complex stability. (b) Rescue of BAF47 leads to a 
widespread gain in BAF complex occupancy, mediating enhancer activation and opposition 
of polycomb-mediated repression at bivalent promoters.
Nakayama et al. Page 26
Nat Genet. Author manuscript; available in PMC 2018 March 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
